IndraLab
Statements
Hydroxychloroquine inhibits SARS-CoV-2 RNA. 6 / 6
|
1
5
reach
"Additionally, hydroxychloroquine in combination with azithromycin has been reported to reduce the detection of SARS-CoV-2 RNA in upper respiratory tract specimens compared to a non randomized control group but did not assess clinical benefit [XREF_BIBR], and in a recent randomized, controlled, open-clinical trial in China, lopinavir and ritonavir did not show promise for the treatment of hospitalized patients with COVID-19 and pneumonia [XREF_BIBR]."
reach
"Studies have been published that hydroxychloroquine has anti-cytokine storm properties.150 In a clinical study involving 36 patients with COVID-19, the use of hydroxychloroquine (200 mg three times a day for 10 days) was shown to decrease SARS-CoV-2 RNA in nasopharyngeal samples compared to the control group on day 6 (70% vs 12.5%).151 In this study, it has been shown that the use of azithromycin in combination with hydroxychloroquine has an additional benefit, however, has not produced sufficient methodological evidence."
reach
"Gautret et al. also reported that Hydroxychloroquine alone or in combination with Azithromycin reduced the detection of SARS-CoV-2 RNA in upper respiratory tract specimens compared with the control group in an open label, non randomized clinical trial [XREF_BIBR] and showed a rapid decline in the detection of SARS-CoV-2 RNA in upper respiratory tract specimens and length of stay in highly contagious wards in his later observational study including 80 patients [XREF_BIBR]."